Neonatal Hyperbilirubinemia Guide

×

1. Introduction

**Neonatal hyperbilirubinemia** (jaundice) is the yellowing of the skin and sclera of the newborn, caused by the deposition of unconjugated bilirubin. It is very common, affecting up to 60% of full-term newborns in the first week of life. Although most cases are benign, severe hyperbilirubinemia is the main cause of hospital readmission. Unconjugated bilirubin can be neurotoxic, causing bilirubin encephalopathy and kernicterus, a serious and irreversible complication. This guideline seeks to prevent severe hyperbilirubinemia in newborns of 35 weeks or more of gestation, balancing early detection with the avoidance of unnecessary treatments.

×

2. Pathophysiology and Classification

2.1. Bilirubin Metabolism in the Neonate

Bilirubin is produced by the breakdown of heme (mainly hemoglobin). In the neonate, production is double that of adults, and the liver function to conjugate it (make it water-soluble and excretable) is immature. This, together with an increase in enterohepatic circulation, favors its accumulation.

2.2. Unconjugated Hyperbilirubinemia (Indirect): Physiological vs. Pathological

**Physiological jaundice:** It is the most common, it appears between 2-3 days and resolves in 2 weeks. It is benign.

**Pathological jaundice:** Indicates an underlying condition. It is pathological if:

• It appears in the **first 24 hours of life**.
• Increases >5 mg/dL/day.
• The newborn has signs of serious illness.

Differentiation is key to avoid overtreatment or underestimating risks.

23. Conjugated Hyperbilirubinemia (Direct)

It is less frequent, but **always pathological**. It is diagnosed if >1.5 mg/dL or >20% of total bilirubin. It does not cause kernicterus, but indicates **severe hepatic or biliary dysfunction** (e.g. biliary atresia), requiring urgent referral to a specialist.

×

3. Etiology and Risk Factors

3.1. Causes of Unconjugated Hyperbilirubinemia

They can be **hemolytic** (ABO/Rh incompatibility, enzyme deficiencies such as G6PD, membrane defects) or **non-hemolytic** (cephalohematomas, inadequate breastfeeding, polycythemia, hypothyroidism, infections, etc.).

3.2. Causes of Conjugated Hyperbilirubinemia

Always pathological: **obstructive** (biliary atresia), **infectious** (TORCH), **genetic** (Alagille), **metabolic** (galactosemia).

3.3. Risk Factors for Severe Hyperbilirubinemia and Neurotoxicity

The combination of factors increases the risk. Identification of these factors is crucial for management and surveillance.

Table 1: Risk Factors for the Development of Significant Hyperbilirubinemia

Risk Category	Specific Factors [1, 2, 15, 18]
Seniors	Jaundice in the first 24 hours of life Maternal-fetal blood group incompatibility with Coombs positive Gestational age <38 weeks (especially 35-36 weeks) Previous brother who required phototherapy Cephalohematoma or significant hematomas Exclusive breastfeeding with excessive weight loss (>10%) or inadequate intake Serum bilirubin level in high-risk zone on Bhutani nomogram before discharge G6PD deficiency
Neurotoxicity	Gestational age <38 weeks Isoimmune hemolytic disease G6PD deficiency Sepsis Acidosis Low serum albumin
Minors	Serum bilirubin level in intermediate-high risk zone before discharge Gestational age 37-38 weeks Jaundice observed before discharge Brother with previous jaundice Macrosomia due to maternal diabetes Maternal age ≥ 25 years Male sex
Additionals/Enhancers	Dehydration Infection Delayed passage of meconium Medications (e.g. maternal oxytocin) Polycythemia
They reduce the risk	Low-risk clinical or serum bilirubin level before discharge Gestational age ≥ 41 weeks Exclusive bottle feeding African American origin Discharge from hospital after 72 hours

×

4. Evaluation and Diagnosis

4.1. History and Detailed Physical Examination

Investigate family, perinatal and postnatal history (appearance of jaundice, feeding, weight loss, feces/urine). The physical examination should be with the baby naked and in good light, **do not use visual estimation**. Look for signs such as lethargy, early jaundice, cephalohematoma, hepatosplenomegaly, or neurological signs.

4.2. Bilirubin Measurement: Transcutaneous Bilirubinometry (BTc) and Total Serum Bilirubin (TBS)

Measurement is mandatory. **BTc** is useful for screening (>24h of life, ≥35 SDG), but not reliable during phototherapy. **BST** is the "gold standard", necessary if jaundice <24h, <35 SDG, elevated BTc, or for monitoring during treatment.

4.3. Interpretation of Bilirubin Levels according to Postnatal Age and Nomograms

Always interpret bilirubin based on the **age in hours** of the neonate, using nomograms and risk factors to guide treatment. Online tools like PediTools/BiliTool are useful.

4.4. Complementary Research

Testing varies by chronology and "red flags."

**Basic tests:** Blood group (mother/baby) and Coombs, CBC and reticulocytes, G6PD (if suspected), Direct/conjugated bilirubin (if prolonged or elevated direct jaundice).

**Additional tests:** Thyroid function, galactosemia screening, urine culture, sepsis markers, serum albumin, electrolytes (according to clinical signs).

4.5. Table: Key Physical Findings in Neonatal Jaundice and Potential Causes

This table correlates clinical findings with chronology and possible causes, aiding differential diagnosis.

Table 2: Key Physical Findings in Neonatal Jaundice and Potential Causes [4, 7, 13, 14]

Physical Findings	Timeline of Jaundice	Suggested Potential Cause
Fever, tachycardia, respiratory distress	First 24 hours; increase > 5 mg/dL/day	Pneumonia, TORCH infection, sepsis
Lethargy, hypotonia	It may appear in the first 24–48 hours; can be prolonged (> 2 weeks)	Hypothyroidism, metabolic disorder, sepsis, bilirubin encephalopathy
Macrosomia	24–48 hours; increase > 5 mg/dL/day	Maternal diabetes
Petechiae	First 24 hours; increase > 5 mg/dL/day	Hemolytic states (incompatibility, enzyme deficiencies, spherocytosis, thalassemia, sepsis)
Plethora	First 24 hours; increase > 5 mg/dL/day	Maternal-fetal or feto-fetal transfusion, delayed cord clamping
Bilateral sloping palpebral fissures, flat nasal bridge, macroglossia, flattened occipital	First 2–3 days; prolonged (>2 weeks)	Down syndrome, Hypothyroidism
Cephalohematoma	24–48 hours; increase > 5 mg/dL/day	Obstetric trauma
Abdominal distention, decreased fluid sounds	Possible delayed manifestation (2–3 days or later)	Intestinal obstruction (cystic fibrosis, Hirschsprung, intestinal atresia/stenosis, pyloric stenosis, biliary atresia)
Persistent yellow urine, cholic/pale stools	Any age, especially prolonged jaundice	Liver disease, biliary atresia

×

Hyperbilirubinemia Calculator and Dynamic Chart

This calculator is a supportive tool and is not a substitute for clinical judgment. The thresholds shown are simplifications based on clinical guidelines and should be interpreted with caution, considering the individual context of each patient. Always consult your institution's complete clinical guidelines and reference nomograms.

×

5. Therapeutic Management

5.1. Primary Prevention and Support of Breastfeeding

Promote exclusive breastfeeding (8-12 feedings/day). Evaluate weight loss >10%. Do not supplement with water/glucose. Monitor weight and intake. Breastfeeding is beneficial despite the risk of jaundice.

5.2. Phototherapy

First-line treatment, transforms bilirubin for excretion. Indicated according to gestational age, age in hours and risk factors.

Guys:

• **Conventional:** A single group of fluorescent lights (8-12 uW/cm²/nm).
• **Intensive:** High radiation levels (≥30 uW/cm²/nm) with maximum exposure (LEDs, blue tubes).
• **Fiber Optic Blanket:** Less effective, but allows breastfeeding.
• **Not recommended:** Sunlight.

Application and Monitoring:

Protect eyes, monitor temperature and hydration. Continue breastfeeding; in intensive phototherapy, supplement with expressed milk if necessary. Measure BST 2-6h after initiation and then every 6-12h.

Adverse Effects:

Dehydration, thermal changes, tan baby syndrome, corneal damage, rash, diarrhea, ileus, lactose intolerance. **Porphyria is an absolute contraindication.**

Interruption:

When BST falls below the threshold in 2 measurements (6-12h interval). Evaluate bilirubin rebound 12-24 hours later, without delaying discharge if there is coordinated follow-up.

5.3. Intravenous immunoglobulin (IVIG)

Consider in **isoimmune hemolytic disease** (Rh/ABO incompatibility) if BST increases rapidly or is near the exchange transfusion threshold. Dose: 0.5-1 g/kg in 2-4 hours; can be repeated in 12 hours.

5.4. exchange transfusion

Rescue procedure for severe hyperbilirubinemia not responding to phototherapy or with signs of acute encephalopathy. It is based on BST thresholds for age in hours and risk factors.

Procedure:

In NICU. Two volumes of the infant's blood are exchanged (2 x 85 ml/kg). Fresh and preheated blood. Discontinue enteral feeding. Monitor glucose, calcium, vital signs.

Complications:

Infection, electrolyte imbalances (common hypocalcemia), transfusion reactions, vascular complications, thrombocytopenia, necrotizing enterocolitis, arrhythmias, heart failure. **Mortality of 1-3%**. It is high risk, so early detection and aggressive phototherapy are emphasized to avoid it.

×

6. Complications of Severe Hyperbilirubinemia

6.1. Acute Bilirubin Encephalopathy: Clinical Manifestations by Stages

Bilirubin crosses the blood-brain barrier, damaging the brain.

• **1st phase (first 48 hours):** Subtle (lethargy, poor diet, decreased Moro reflex).
• **Intermediate phase (half of the 1st week):** Extensor hypertonia, opisthotonos, fever, high-pitched crying.
• **Advanced phase (after 1st week):** Persistent hypertonia, seizures, coma.

Early detection and treatment are vital to prevent irreversible damage.

6.2. Kernicterus (Chronic Bilirubin Encephalopathy): Long-Term Neurological Sequelae

Permanent brain damage from bilirubin (basal ganglia, cerebellum). It's preventable, but it still happens.

Aftermath:

Cerebral palsy, developmental delay, **hearing deficit** (most common), dental dysplasia, oculomotor disorders, extrapyramidal symptoms, seizures. It highlights the need to adhere to guidelines and parental education to prevent cases.

×

7. Follow-up and Hospital Discharge

7.1. Severe Hyperbilirubinemia Risk Assessment Before Discharge

It is essential to evaluate the risk of severe hyperbilirubinemia in all newborns before discharge, especially if it is before 72 hours. Measure BST/BTc at least 12 hours post-birth and interpret with nomograms. Provide information to parents.

7.2. Post-Discharge Monitoring Plan: Timing and Content of Visits

All newborns should be checked by a professional. Tracking times:

• **Discharge <24h:** Review before 72h of life.
• **Discharge 24-47.9h:** Review before 96h of life.
• **Discharge 48-72h:** Review before 120h of life.

If there is high risk, closer follow-up (24-48h). Bilirubin rebound is monitored 12-18 hours post-phototherapy, without delaying discharge if there is a clear follow-up plan.

7.3. Long-Term Follow-Up for Infants with Severe Hyperbilirubinemia or Kernicterus

• **Late Anemia:** Control hemoglobin in cases of isoimmunization. Supplement folic acid if hemolysis.
• **Prolonged jaundice (>14 days in term, >3 weeks in premature babies):** Evaluate urgently (fractionated bilirubin, blood count, thyroid, etc.). Cholic stools or dark urine require urgent referral.
• **Neurological Sequelae (Kernicterus):** Vital neurodevelopmental monitoring to identify and manage long-term sequelae. Tests such as BAER and brain MRI may be helpful.

×

8. Conclusion: Key Points for Clinical Practice

• **Do not rely on visual evaluation**; always measure bilirubin (BTc/BST) and use age in hours.
• **Supporting breastfeeding** is a key prevention.
• **Phototherapy is the mainstay of treatment**; apply it intensively and monitor.
• **Exchange transfusion is a high-risk last resort**; avoid it with early management.
• **Early risk identification** and **individualized post-discharge follow-up** are crucial.
• **Prolonged jaundice or elevated conjugated bilirubin** always require investigation and referral.
• **Educating parents** about jaundice and the warning signs is vital.